<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="71699"><DrugName>ARH-1</DrugName><DrugSynonyms><Name><Value>ARH-1</Value></Name><Name><Value>arteether (injectable, malaria), Lincoln</Value></Name></DrugSynonyms><CompanyOriginator id="DOL1000801">Lincoln Pharmaceuticals Ltd</CompanyOriginator><CompaniesPrimary><Company id="DOL1000801">Lincoln Pharmaceuticals Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="71699" type="Drug"><TargetEntity id="693101" type="siDrug">ARH1</TargetEntity></SourceEntity><SourceEntity id="DOL1000801" type="Company"><TargetEntity id="4295872217" type="organizationId">Lincoln Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="268" type="ciIndication"><TargetEntity id="10025487" type="MEDDRA"/><TargetEntity id="673" type="ORPHANET"/><TargetEntity id="-2144313480" type="omicsDisease"/><TargetEntity id="850" type="siCondition"/></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Plasmodium infection - India - Jun-2011</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="268">Plasmodium infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="2638">Antiparasitic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="596">Injectable formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2013-08-23T10:13:47.000Z</LastModificationDate><ChangeDateLast>2011-06-07T15:26:47.000Z</ChangeDateLast><AddedDate>2011-06-07T14:25:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="DOL1000801"&gt;Lincoln Pharmaceuticals&lt;/ulink&gt; has launched ARH-1, an injectable formulation of arteether, developed using Dose Optimization Technology for the treatment of malaria. The drug was launched in India in June 2011 [&lt;ulink linkType="Reference" linkID="1197998"&gt;1197998&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By June 2011, clinical trials in more than 280 patients demonstrated  the efficacy of ARH-1 in comparison to leading market brands [&lt;ulink linkType="Reference" linkID="1197998"&gt;1197998&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="DOL1000801">Lincoln Pharmaceuticals Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="268">Plasmodium infection</Indication><StatusDate>2011-06-02T00:00:00.000Z</StatusDate><Source id="1197998" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>